B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2 DOI Creative Commons
Beatriz Perdiguero, Enrique Álvarez, Laura Marcos-Villar

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(11), P. 1213 - 1213

Published: Oct. 25, 2024

Background: The COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the need for vaccines targeting both neutralizing antibodies (NAbs) and long-lasting cross-reactive T cells covering multiple viral proteins to provide broad durable protection against emerging variants. Methods: To address this, here we developed two vaccine candidates, namely (i) DNA-CoV2-TMEP, expressing multiepitopic CoV2-TMEP protein containing immunodominant conserved cell regions from SARS-CoV-2 structural proteins, (ii) MVA-CoV2-B2AT, encoding a bi-cistronic construct that combines B overlapping proteins. Results: Both candidates were assessed in vitro vivo demonstrating their ability induce robust immune responses. In C57BL/6 mice, DNA-CoV2-TMEP enhanced recruitment of innate stimulated SARS-CoV-2-specific polyfunctional MVA-CoV2-B2AT elicited NAbs various variants concern (VoCs) reduced replication yields Beta variant susceptible K18-hACE2 mice. combination with mutated ISG15 form as an adjuvant further increased magnitude, breadth profile response. Conclusion: These findings underscore potential these when expressed DNA or MVA vectors its variants, supporting development next-generation vaccines.

Language: Английский

An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza DOI Creative Commons
Man Xing, Gaowei Hu, Xiang Wang

et al.

npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)

Published: March 21, 2024

Abstract Despite prolonged surveillance and interventions, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) influenza viruses continue to pose a global health burden. Thus, we developed chimpanzee adenovirus-based combination vaccine, AdC68-HATRBD, with dual specificity against SARS-CoV-2 virus. When used as standalone intranasal immunization AdC68-HATRBD induced comprehensive potent immune responses consisting of immunoglobin (Ig) G, mucosal IgA, neutralizing antibodies, memory T cells, which protected mice from BA.5.2 pandemic H1N1 infections. heterologous booster, markedly improved protective response licensed or vaccine. Therefore, whether administered intranasally booster this vaccine is valuable strategy enhance overall efficacy by inducing robust systemic responses, thereby conferring lines immunological defenses for these two viruses.

Language: Английский

Citations

17
T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases DOI Creative Commons

Xin Song,

Yongfeng Li,

Hongxia Wu

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(10), P. 1181 - 1181

Published: Oct. 17, 2024

With the development of novel vaccine strategies, T-cell epitope-based vaccines have become promising prophylactic and therapeutic tools against infectious diseases that cannot be controlled via traditional vaccines. leverage specific immunogenic peptides to elicit protective responses pathogens. Compared vaccines, they provide superior efficacy safety, minimizing risk adverse side effects. In this review, we summarized compared prediction identification methods epitopes. By integrating bioinformatic experimental validation, efficient precise screening epitopes can achieved. Importantly, delved into approaches diverse comparing their merits demerits, as well discussing prevalent challenges perspectives in applications. This review offers fresh for formulation safe efficacious devastating which no are currently available.

Language: Английский

Citations

7
Broad Mucosal and Systemic Immunity in Mice Induced by Intranasal Booster With a Novel Recombinant Adenoviral Based Vaccine Protects Against Divergent Influenza A Virus DOI Open Access
Jia Li,

Tangqi Wang,

Xiaojuan Guo

et al.

Journal of Medical Virology, Journal Year: 2025, Volume and Issue: 97(4)

Published: March 27, 2025

ABSTRACT The development of broad‐spectrum universal influenza vaccines and optimization vaccination strategies to address the threats posed by pandemics emerging viruses are critical for public health. In this study, an adenovirus type 5 vector‐based vaccine carrying hemagglutinin (HA) stem H1, HA H3, neuraminidase (NA) N1 from virus was constructed. Immune responses were evaluated in mice using various strategies: prime‐only (intramuscular [IM] or intranasal [IN]) prime‐boost (IM + IN). Compared with strategy, strategy significantly enhanced systemic immune response, inducing higher levels antigen‐specific IgG, mucosal IgA, T cell immunity spleen lungs. Furthermore, IN boosting provided complete protection challenged H1N1‐PR8, rgH3N2‐X31, rgH5N1‐Vietnam viruses, reducing viral loads lungs alleviating lung tissue pathologies. conclusion, study elucidates potential avenues application customized strategies.

Language: Английский

Citations

0
CD8+ T cell-based immunotherapy: Promising frontier in human diseases DOI

Nu Quynh Chau Ton,

Gitima Deka,

Pil‐Hoon Park

et al.

Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 116909 - 116909

Published: April 1, 2025

Language: Английский

Citations

0
Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2 DOI Creative Commons

Muralimanohara S. T. Murala,

Vivek Gairola,

Ekramy E. Sayedahmed

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 406 - 406

Published: April 14, 2025

This review systematically revises adenovirus (Ad) biology, vector structure, immune responses, and currently available Ad COVID-19 vaccines. It analyzes the challenges associated with vector-based vaccines, including preexisting immunity other side effects. Moreover, this explores novel innovative strategies to overcome these constraints for developing next-generation vaccines broad protection cover emerging SARS-CoV-2 variants. The future refinement of vaccine platforms will be pivotal in achieving durable against variants global preparedness.

Language: Английский

Citations

0
A quadrivalent norovirus vaccine based on a chimpanzee adenovirus vector induces potent immunity in mice DOI Creative Commons

Yihua Jiang,

Lingjin Sun,

Nan Qiao

et al.

Virologica Sinica, Journal Year: 2024, Volume and Issue: 39(4), P. 675 - 684

Published: July 10, 2024

Norovirus (NoV) infection is a major cause of gastroenteritis worldwide. The virus poses great challenges in developing vaccines with broad immune protection due to its genetic and antigenic diversity. To date, there are no approved NoV for clinical use. Here, we aimed develop broad-acting quadrivalent vaccine based on chimpanzee adenovirus vector, AdC68, carrying the capsid protein (VP1) noroviral GI GII genotypes. Compared intramuscular (i.m.), intranasal (i.n.), or other prime-boost immunization regimens (i.m. ​+ ​i.m., i.m. ​i.n., i.n. ​i.m.), AdC68-GI.1-GII.3 (E1)-GII.4-GII.17 (E3), administered via ​i.n. induced higher titers serum IgG antibodies IgA bronchoalveolar lavage fluid (BALF) saliva against four homologous VP1s mice. It also significantly stimulated production blocking In response re-stimulation virus-like particles (VLP)-GI.1, VLP-GII.3, VLP-GII.4, VLP-GII.17, according regimen effectively triggered specific cell-mediated responses, primarily characterized by IFN-γ secretion. Furthermore, preparation this novel requires only single recombinant provide preventive immunity GI/GII epidemic strains, making it promising candidate further development.

Language: Английский

Citations

2
B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2 DOI Creative Commons
Beatriz Perdiguero, Enrique Álvarez, Laura Marcos-Villar

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(11), P. 1213 - 1213

Published: Oct. 25, 2024

Background: The COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the need for vaccines targeting both neutralizing antibodies (NAbs) and long-lasting cross-reactive T cells covering multiple viral proteins to provide broad durable protection against emerging variants. Methods: To address this, here we developed two vaccine candidates, namely (i) DNA-CoV2-TMEP, expressing multiepitopic CoV2-TMEP protein containing immunodominant conserved cell regions from SARS-CoV-2 structural proteins, (ii) MVA-CoV2-B2AT, encoding a bi-cistronic construct that combines B overlapping proteins. Results: Both candidates were assessed in vitro vivo demonstrating their ability induce robust immune responses. In C57BL/6 mice, DNA-CoV2-TMEP enhanced recruitment of innate stimulated SARS-CoV-2-specific polyfunctional MVA-CoV2-B2AT elicited NAbs various variants concern (VoCs) reduced replication yields Beta variant susceptible K18-hACE2 mice. combination with mutated ISG15 form as an adjuvant further increased magnitude, breadth profile response. Conclusion: These findings underscore potential these when expressed DNA or MVA vectors its variants, supporting development next-generation vaccines.

Language: Английский

Citations

0